Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 8th, 2020

Late-Breaking Science to headline Scientific Sessions

The lineup of planned Late-Breaking Science is stronger this year than ever before.


Getty Images 973136992

The lineup of planned Late-Breaking Science is stronger this year than ever before. Here are the nine featured late-breaking science presentations. Check the Online Program Planner for times and dates of the presentations.

LBS.01: Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients and More

  • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial — GALACTIC-HF
  • Ferric Carboxymaltose in Iron Deficient Patients Admitted for Acute Heart Failure — AFFIRM-AHF
  • The Vital Rhythm Trial: Omega-3 Fatty Acid and Vitamin D Supplementation in the Primary Prevention of Atrial Fibrillation — VITAL Rhythm

LBS. 02: Bending the Curve for CV Disease — Precision or PolyPill?

  • A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3 — TIPS-3
  • Aspirin Alone and in Combination With a Polypill in Cardiovascular Disease Primary Prevention: Results From the International Polycap Study (TIPS)-3 — TIPS-3
  • Prevalence and Prediction of Coronary Artery Disease in the General Population — Results From the Swedish Cardiopulmonary Bioimage Study (scapis) — SCAPIS

LBS.03: Current Challenges in Coronary and Valve Disease

  • Ticagrelor Versus Clopidogrel in Elective Percutaneous Coronary Intervention: The Alpheus Trial — ALPHEUS
  • Coronary OCT and Cardiac MRI to Determine Underlying Causes of MINOCA in Women — HARP — Women’s Heart Attack Research Program

LBS.04: Fish Oil, Fancy Drugs and Frustrations in Lipid Management

  • STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) in Patients With High Vascular Risk and Atherogenic Dyslipidemia — STRENGTH
  • Effects of N-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in the Elderly: Results of the Omemi Trial — OMEMI 
  • A Three-Arm N-of-1 Trial With Statin, Placebo and Tablet Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial — SAMSON
  • The Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

LBS.05: Stents, Valves and Clots

  • A Prospective Multicenter Randomized Controlled Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System in Patients With Stable or Non-ST Elevation Acute Coronary Syndromes: Primary Endpoint Results of the PIONEER III Trial — PIONEER III
  • One-Month Dual Antipletelet Therapy Followed by Aspirin Monotherapy After Drug Eluting Stent Implantation — One-Month DAPT trial
  • Rivaroxaban Versus Warfarin in Patients With Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results From the RIVER Randomized Trial — RIVER Trial

LBS.06: To Screen or Not to Screen, and Then What?  Studies of Detection and Treatment of AF

  • Enhanced Monitoring for Atrial Fibrillation Following Cardiac Surgery: Primary Results of The SEARCH-AF Cardiolink Randomized Trial — SEARCH-AF
  • Screening for Atrial Fibrillation in Older Adults at Primary Care Visits Using Single Lead Electrocardiograms: The VITAL-AF Trial — VITAL-AF
  • 3-Year Clinical Outcomes in a Nationwide, Randomized, Pragmatic Clinical Trial of Atrial Fibrillation Screening — Mhealth Screening to Prevent Strokes (mstops) — mSToPS
  • Early Invasive Intervention for Atrial Fibrillation — EARLY-AF

LBS.07: Randomized Trials — Brain, Kidney and Heart

  • Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes — FIDELIO-DKD
  • Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Tia of Atherosclerotic Origin —THALES
  • RHAPSODY: Rilonacept an IL-1α and IL-1β Trap Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients With Recurrent Pericarditis — RHAPSODY
  • Rapid Assessment of Potential Ischemic Heart Disease With CTCA: The Rapid-CTCA Trial. A Randomized Trial of CTCA in the Evaluation, Intervention and Outcome of Adults With Suspected or Confirmed Acute Coronary Syndrome Presenting to the Emergency Department — RAPID-CTCA
  • SOLOIST-WHF: Sotagliflozin in Diabetes Patients with Recent Worsening Heart Failure – SOLOIST-WHF
  • SCORED: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease – SCORED

LBS.08: AHA Goes Viral: COVID-19, Influenza Vaccines and Cardiovascular Disease

  • The AHA COVID-19 Cardiovascular Disease Registry: Design, Implementation and Initial Results
  • Racial and Ethnic Differences in Treatment and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association COVID-19 Cardiovascular Disease Registry
  • Association of Body Mass Index With Death, Mechanical Ventilation and Cardiovascular Outcomes in COVID-19: Findings From the AHA COVID-19 Cardiovascular Disease Registry
  • Impact of Cardiovascular Disease on Outcomes Among Hospitalized COVID-19 Patients: Results From >14,000 Patients Across the United States
  • High Dose Versus Standard Dose Influenza Vaccine in Patients With High Risk Cardiovascular Disease: Results From the Invested Trial — INVESTED

LBS.09: High Tech or High Touch: Creative Strategies to Optimize Patient Care

  • An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial — EPIC-HF
  • My Recorded On-Demand Audio Discharge Instructions (MyRoad) In Heart Failure — MYROAD
  • Digital Care Transformation: One-Year Report of >5,000 Patients Enrolled in a Remote Algorithm-Based CV Risk Management Program to Achieve Optimal Lipid and Hypertension Control
  • Group Medical Visits and Microfinance for Patients With Diabetes and Hypertension in Western Kenya: Results of the BIGPIC Trial — BIGPIC
Interesting Stories
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
More Content
attentive audience
AHA24
Find inspiration at the #AHA24Main Events
Oct 23rd, 2024
late breaking science audience and presentation
Previews
#AHA24 Late-Breaking and Featured Science announced
Sep 30th, 2024
AHA crowds
Previews
Become a professional member
Sep 20th, 2024
abstracts of fraudulent activity
Previews
Beware of fraudulent website and booking scams
Sep 20th, 2024
Early Career Audience
Previews
Pre-Sessions Symposia and Early Career Day
Sep 20th, 2024
Networking attendees
Previews
Network with your colleagues at #AHA24
Sep 20th, 2024
Simulation zone with audience
Previews
Simulation Zone
Sep 20th, 2024
keyboard with a register button
Previews
Register today for #AHA24!
Sep 20th, 2024
Lansing page for virtual platform
AHA22
Watch: Scientific Session Virtual Platform tour
Nov 1st, 2022
Aha22 Sm 0083
AHA22
Thought leaders to inspire at Main Events
Oct 14th, 2022
Health Pavilion
AHA22
Visit the Health Innovation Pavilion
More about the Health Innovation Pavilion
Oct 28th, 2022
Symposia locator cover
AHA22
AHA Scientific Sessions 2022 Symposia Schedule and Locator Guide
Oct 24th, 2022